MANY MINDEDJ&J's surgical robot clears FDA, ending Intuitive's near-monopoly
On July 23, 2026, the US FDA authorized Johnson & Johnson's Ottava Robotic Surgical System, according to reporting from Fierce Biotech. The clearance covers a broad set of soft-tissue procedures, including gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication, and hiatal hernia repair. J&J plans a limited commercial launch with select US customers rather than a full rollout, and a separate US trial for an inguinal hernia indication is ongoing.
Ottava's design integrates four robotic arms directly into a standard-size surgical table, eliminating the separate booms or carts that other systems require. The system enters a market long dominated by Intuitive Surgical's da Vinci robot, alongside competitors from Medtronic and CMR Surgical.
Minimally invasive robotic surgery has been constrained partly by the cost and lock-in of a single dominant platform. A credible second entrant from a large medtech player gives hospitals negotiating leverage and could, over time, push down the price of robotic procedures and widen access to less-invasive surgery for more patients.
What to watch is whether Ottava wins real adoption. J.P. Morgan analyst Robbie Marcus, in a note to clients, said the firm still views da Vinci as the system of choice, citing entrenched physician relationships and hospital integration. J&J is pursuing additional indications and regulatory jurisdictions over time, so the competitive impact will unfold across years, not months.
Source: Fierce Biotech